The Target-MRD blood test uses a combination of tumor-informed and tumor-agnostic molecular features for personalized, accurate and more effective monitoring of molecular residual disease. LONDON and MUNICH and NEW DELHI, Jan. 21, 2025 /PRNewswire/ — Datar Cancer Genetics (DCG) today…